

# From Pathogens to Prescriptions:

## Foundations of Antimicrobial Therapy

April 2026

# What does “Pathogens to Prescriptions” really mean?

## Basically: Bug to Drug

Why it matters:

- Prevents resistance
- Improves patient outcomes
- Reduces adverse effects



# Objectives:

- Review principles of antibiotic selection
- Identify common pathogens and the type of infections they cause
- Analyze common outpatient antibiotics and their spectrum of activity




# Principles of Antibiotic Selection

## The 4 Moments of Antibiotic Decision-Making (per CDC framework)

1. Does the person have an infection that requires antibiotics?
2. Have appropriate cultures been collected before starting antibiotics?
3. What empiric therapy should be started?
4. Can the antibiotic be stopped or narrow therapy based on data?

# Key Considerations

- Site of Infection
- Likely Pathogen
- Local Resistance Patterns  
Review Antibiogram
- Patient Factors  
Allergies  
Renal/hepatic function  
Comorbidities



Distribution of normal flora of the human body

# Stages of Antimicrobial Therapy

## Prophylaxis

- Antimicrobial given to prevent an infection that hasn't happened yet, but is likely to happen without medication
- Immunocompromised patients, pre-procedural

## Empiric therapy

- Based upon body location, most common pathogens in that area, and symptoms

## Definitive therapy

- After culture/sensitivity results are known

**The Old Pick-an-Antibiotic-Card Trick! I Love Magic!**



# Common Pathogens

*A little microbiology review*

# Microbiology Review

## Gram-positive bacteria

- Thick peptidoglycan layer, retain crystal violet stain (purple)

## Gram-negative bacteria

- Thin peptidoglycan layer, stain pink on gram stain

## Fungi

- Yeast & Molds
- Can be single celled or very complex multicellular organisms

## Viruses

- Require a living host cell to replicate






**What pathogens do you commonly encounter in your practice?**



# Gram Positive Bacteria



# Gram Positive Bacteria

## Staphylococcus

### *S. aureus*

Causes skin/soft tissue infections, bone/joint infections, endocarditis


Can be methicillin susceptible or resistant (MSSA vs MRSA)

### *S. Epidermidis*

Usually a colonizer

May cause infections associated with prostheses and IV lines

- Both may colonize skin and nares
- Both will produce sticky biofilm and may lead to widespread invasive infections



# Treatment Options

## MSSA

ORAL: Cephalexin, cefadroxil, dicloxacillin, amoxicillin/clavulanate

IV: Cefazolin, oxacillin, nafcillin

## MRSA

Oral: SMX/TMP, doxycycline, clindamycin, linezolid

IV: Vancomycin, daptomycin, ceftaroline

Image from [prescribingpractice.com](https://www.prescribingpractice.com) Accessed March 2026



# Infection Prevention Considerations

## Staphylococcus

### Transmission Based Precautions

MSSA: Standard

MRSA (multi-drug resistant organism): Standard and Contact precautions

Tip: Flag charts as MRSA for staff awareness

\*\*Vancomycin resistant and intermediate resistance *S. aureus* is a reportable disease\*\*

Infection/Condition	Type of Precaution	Duration of Precaution	Precautions/Comments
Staphylococcal disease ( <i>S. aureus</i> ) Skin, wound, or burn Major	Contact + Standard	Duration of illness	Until drainage stops or can be contained by dressing.
Staphylococcal disease ( <i>S. aureus</i> ) Skin, wound, or burn Minor or limited	Standard		If dressing covers and contains drainage adequately.
Staphylococcal disease ( <i>S. aureus</i> ) Enterocolitis	Standard		Use Contact Precautions for diapered or incontinent children for duration of illness.
Staphylococcal disease ( <i>S. aureus</i> ) Multidrug-resistant (see Multidrug-Resistant Organisms)			
Staphylococcal disease ( <i>S. aureus</i> ) Pneumonia	Standard		
Staphylococcal disease ( <i>S. aureus</i> ) Scalded skin syndrome	Contact + Standard	Duration of illness	Consider healthcare personnel as potential source of nursery, NICU outbreak [1095].
Staphylococcal disease ( <i>S. aureus</i> ) Toxic shock syndrome	Standard		

# Gram Positive Bacteria

## Streptococcus

Beta hemolytic


*S. pyogenes* (Group A strep)

*S. agalactae* (Group B strep)

Alpha hemolytic

*S. viridans*

- Colonize skin, mouth (*S. viridans*), and female reproductive tract (*S. agalactae*)
- Infections:
  - Skin and soft tissue infections
  - Neonatal sepsis
  - Bone/joint infection
  - Endocarditis
  - Upper respiratory (pharyngitis, otitis media, sinusitis, bronchitis)
  - Pneumonia



# Gram Positive Bacteria

## Streptococcus pneumoniae

### Transmission Based Precaution

- Dependent on source

Prevent infection with pneumococcal conjugate vaccine (PCV)

Infection/Condition	Type of Precaution	Duration of Precaution	Precautions/Comments
<i>Streptobacillus moniliformis</i> disease (rat-bite fever)	Standard		Not transmitted from person to person.
Streptococcal disease (group A <i>Streptococcus</i> ) Skin, wound, or burn Major	Contact + Droplet + Standard	Until 24 hours after initiation of effective therapy	Until drainage stops or can be contained by dressing.
Streptococcal disease (group A <i>Streptococcus</i> ) Skin, wound, or burn Minor or limited	Standard		If dressing covers and contains drainage.
Streptococcal disease (group A <i>Streptococcus</i> ) Endometritis (puerperal sepsis)	Standard		
Streptococcal disease (group A <i>Streptococcus</i> ) Pharyngitis in infants and young children	Droplet + Standard	Until 24 hours after initiation of effective therapy	
Streptococcal disease (group A <i>Streptococcus</i> ) Pneumonia	Droplet + Standard	Until 24 hours after initiation of effective therapy	
Streptococcal disease (group A <i>Streptococcus</i> ) Scarlet fever in infants and young children	Droplet + Standard	Until 24 hours after initiation of effective therapy	
Streptococcal disease (group A <i>Streptococcus</i> ) Serious invasive disease	Droplet + Standard	Until 24 hours after initiation of effective therapy	Outbreaks of serious invasive disease have occurred secondary to transmission among patients and healthcare personnel [162, 972, 1096-1098]. Contact Precautions for draining wound as above; follow recommendations for antimicrobial prophylaxis in selected conditions [160].
Streptococcal disease (group B <i>Streptococcus</i> ), neonatal	Standard		
Streptococcal disease (not group A or B) unless covered elsewhere Multidrug-resistant (see Multidrug-Resistant Organisms)			

# Gram Positive-Enterococci


## E. Faecalis

More common  
Less likely to be vancomycin resistant (VRE)

## E. Faecium

Less common  
More likely to be VRE

- May colonize lower GI tract
- May cause UTI, intraabdominal infections, meningitis, and endocarditis
- Susceptible to only a selected number of antibiotics  
Especially *E. faecium*



# Antibiogram

INPATIENT ORGANISMS	Isolates Tested	PCN G IV (nonmeningitis)	PCN (meningitis and PO dosing)	Ampicillin	Oxacillin	Ampicillin/sulbactam	Piperacillin/tazobactam	Cefazolin (non-urine)	Cefazolin (urine)	Ceftriaxone (non-meningitis)	Ceftriaxone (Meningitis)	Ceftazidime	Cefepime	Meropenem	Gentamicin 1	Tobramycin	Levofloxacin	Ciprofloxacin	Vancomycin	Clindamycin	TMP/SMX	Doxycycline	Nitrofurantoin (Urine isolates only)
	Enterococcus faecalis	87			100											80		85	85	100			
Enterococcus faecium	24			13											96		9	9	50				39

Gram-positive % susceptible	No. Isolates	Penicillin IV (non-meningitis/ meningitis)	Penicillin	Ampicillin	Oxacillin	Piperacillin/tazobactam	Cefotaxime/Ceftriaxone (non-meningitis/ meningitis)	Erythromycin	TMP/SXT	Clindamycin	Doxycycline/Tetracycline	Vancomycin	Linezolid	Daptomycin <sup>4</sup>	Nitrofurantoin (Urine only)
		E. faecalis	359			100		See amp						99	98
E. faecium	57			28								61	97	Not tested	30

# Infection Prevention Considerations

## Enterococci


### Transmission Based Precautions

- Non-vancomycin resistant enterococci
  - Standard precautions
- VRE
  - Standard and contact precautions
  - Reportable to NDHHS
  - Flag chart for staff awareness

Infection/Condition	Type of Precaution	Duration of Precaution	Precautions/Comments
Multidrug-resistant organisms (MDROs), infection or colonization (e.g., MRSA, VRE, VISA/VRSA, ESBLs, resistant <i>S. pneumoniae</i> )	Contact + Standard		MDROs judged by the infection control program, based on local, state, regional, or national recommendations, to be of clinical and epidemiologic significance. Contact Precautions recommended in settings with evidence of ongoing transmission, acute care settings with increased risk for transmission or wounds that cannot be contained by dressings. See recommendations for management options in Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006 [870]. Contact state health department for guidance regarding new or emerging MDRO.



# Gram Negative Bacteria



**GRAM PROJECT**

# Gram Negative Bacilli

## Endogenous

Part of normal GI tract

May colonize upper respiratory tract of hospitalized patients

May cause:

- UTIs

- Respiratory tract infection

- Intra-abdominal infections

- Diabetic lower extremity infections

*Escherichia coli*

*Serratia sp.*

*Citrobacter sp.*

*Klebsiella sp.*

*Proteus sp.*

*Enterobacter sp.*

# Gram Negative Bacteria

## Exogenous

NOT colonizers

Contracted from other sources

May cause:

Upper and lower respiratory infections

*H. influenzae*

*M. catarrhalis*

*Acinetobacter sp.*

Sexually transmitted disease

*N. gonorrhoea*

Bacterial meningitis

*N. meningitidis*

*Haemophilus influenzae*

*Moraxella catarrhalis*

*Acinetobacter sp.*

*Neisseria meningitidis*

*Neisseria gonorrhoea*

# Gram Negative Pseudomonas

## *Pseudomonas aeruginosa*

Not a normal human colonizer

**May colonize GI tract in 10-20%**

**May colonize respiratory tract of some patient**

**Cystic fibrosis**

**Hospitalized patients**

Colonizes inanimate objects

**Water**

**Medical equipment**

Opportunistic pathogen



# Gram Negative Pseudomonas

## *Pseudomonas aeruginosa*

May cause

- UTI's

- Pneumonia

- Intra-abdominal infections

- Diabetic lower extremity infections

“Hospital bug”

More common in patients who have received multiple courses of antibiotics or exposed to the healthcare system



# Infection Prevention Considerations

## *Pseudomonas aeruginosa*

Transmission Based Precautions:

Contact vs Enhanced Barrier Precautions

If carbapenem resistant, reportable to NDHHS

Important to clean and disinfect patient environment and medical equipment

Prevent transmission from sinks, toilets, and other wastewater plumbing



### Timely and Accurate Identification of Patients with CRPA

- Ensure your clinical laboratory can identify CRPA.
- Ask your health department about the availability of specialized testing through CDC's AR Lab Network to identify carbapenemase-producing CRPA from clinical cultures and to screen for CRPA colonization.
- Follow public health recommendations for CRPA colonization screening.
- When transferring a patient colonized or infected with CRPA, notify accepting facilities and units of the patient's CRPA history.
- Work with your health department to understand local CRPA epidemiology.



### Perform Hand Hygiene

- Clean your hands immediately before touching a patient, before performing an aseptic task (e.g., placing an indwelling device), before handling invasive medical devices, and before moving from work on a soiled body site to a clean body site on the same patient.
- Perform hand hygiene after touching a patient or the patient's immediate environment; after contact with blood, body fluids, or contaminated surfaces; and immediately after glove removal.

#### Did you know?

Alcohol-based hand sanitizers are the preferred method for cleaning your hands in most clinical situations. Wash your hands with soap and water whenever they are visibly dirty, before eating, and after using the restroom.



### Wear Gown & Gloves When Caring for Patients with CRPA

CRPA can contaminate your hands and clothes while you care for a patient with CRPA or work in their environment. This puts the patients who you care for afterward at risk of acquiring CRPA.

- Protect your patients by wearing a gown and gloves for patient care according to the guidelines for your setting (i.e., Contact Precautions in acute care, Enhanced Barrier Precautions in long-term care).
- Don and doff your personal protective equipment (PPE) in the right order and take care not to self-contaminate during doffing.
- Always change your PPE between patients or residents.



### Clean and Disinfect the Patient Environment and Medical Equipment

- Follow your facility's cleaning and disinfection protocols.
- Ensure high-touch surfaces (e.g., bed rails, light switches, call buttons) are cleaned frequently.
- Dedicate non-critical medical equipment (e.g., stethoscopes, blood pressure cuffs) to CRPA patients whenever possible and always clean and disinfect between patients.
- Ensure shared medical equipment is cleaned and disinfected after each use.



### Prevent Transmission from Sinks, Toilets, and Other Wastewater Plumbing

CRPA can contaminate wastewater plumbing, especially sink drains, toilets, and hoppers. Water splashes from these sources has been associated with outbreaks of carbapenemase-producing organisms.

- Clean and disinfect countertops, handles, faucets, and sink basins at least daily.
- Keep patient care items at least three feet away from sinks, toilets, and hoppers.
- Do not discard patient waste in sinks.
- Avoid discarding beverages or other sources of nutrients in sinks or toilets.

# Fungi

## *Candida Auris*

Can live on surfaces for a long time

Transmitted person-to-person, via contaminated surfaces or medical equipment

Causes ear infections, UTIs, wound infections, or bloodstream infections



# Infection Prevention Considerations

## *C. auris*

Immediately report any confirmed *C. auris* test results to the public health department.

### Transmission Based Precautions

- Contact precautions/Enhanced barrier precautions

- Dedicated medical equipment

- Flag charts for staff awareness and communicate *C. auris* status during transfers

- Ensure cleaning/disinfecting agents are on EPA list P

### Outbreaks

- May need to screen patients/residents for *C. auris* colonization

- Use the same infection control measures for patients found to be colonized.

# Common Antibiotics



**What antibiotic does your facility use the most?**

# Common Antibiotics

## Beta-lactam antibiotics



# Beta-lactam Antibiotics

## Penicillin & cephalosporins

Tend to accumulate well at sites of infection:

- Respiratory tract

- Urinary tract (most in very high concentrations)

Toxicity is pretty minimal

- Diarrhea is fairly common

- Allergy is the most common major issue

Most are inexpensive, available in liquid, usually taste OK to good

# Beta-Lactam Antibiotic

## Amoxicillin

Dosing: Usually twice daily

Toxicity: Minimal (Allergy)

C. Diff risk: Low

### Guideline Recommendations

First line for:

- Pediatric acute otitis media
- Pediatric acute bacterial sinusitis
- Streptococcal pharyngitis
- CAP (if “healthy” individual)

\*\*Should be most commonly prescribed antibiotic, especially in pediatrics\*\*



# Beta-Lactam Antibiotic

## Amoxicillin-Clavulanate

Dosing: Usually twice daily

Toxicity: Allergy/Diarrhea

C. Diff risk: Low-moderate

Guideline Recommendations

First line for:

- Acute bacterial sinusitis
- Adult CAP
- COPD exacerbation
- Bite wound (prophylaxis or treatment)

\*Should be commonly prescribed

\*Adds H. flu, Moraxella and anaerobic coverage to Amoxicillin



# Beta-Lactam Antibiotic

## Cephalexin

Dosing: Three to four time a day dosing (twice daily for strep throat)

Toxicity: Well tolerated

C. Diff risk: Low

Guideline Recommendations


First line for:

- Cellulitis and erysipelas
- Abscess with low risk of MRSA

Also commonly used for:

- Non severe UTI
- Streptococcal pharyngitis

\*High urinary concentrations thus can use for E.coli and other gram negative UTI's.



# Beta-Lactam Antibiotic

## Cefdinir

Dosing: Usually twice daily, may be daily

Toxicity: Diarrhea (turns stool red)

C. Diff risk: Moderate

Guideline Recommendations

First line for:

- NOTHING

Commonly used when amox or amox/clav is first line but there is a penicillin allergy

Only 10-20% is excreted in urine but is often used for UTIs



# Other Common Antibiotics



# Macrolide Antibiotic

## Azithromycin

Dosing: Long half life Max duration 5 days  
Toxicity: Some nausea, vomiting, diarrhea, QT prolongation  
C. Diff risk: Very low

### Guideline Recommendations


First line for:

- Adult CAP in combination with Amox/clav
- COPD Exacerbation
- Pertussis

Commonly used for:

- Bacterial Diarrhea
- Streptococcal pharyngitis (watch resistance rates)

Used for atypical coverage and in combination for respiratory infections



# Lincosamide Antibiotic

## Clindamycin

Dosing: Three times a day

Toxicity: GI intolerance and diarrhea common


C. Diff risk: HIGH

### Guideline Recommendations

Commonly used for:

- Dental infections and streptococcal pharyngitis when a beta-lactam alternative needed
- Skin and soft-tissue infections

NOTE: Rising resistance in *S. aureus*



# Folate Antagonist Antibiotic


## Trimethoprim-Sulfamethoxazole

Dosing: Twice a day  
Need to adjust if GFR <30  
Toxicity: Rare/severe (Stevens-Johnson, neutropenia, anaphylaxis), Hyperkalemia(esp. in renal dysfunction)  
C. Diff risk:Low

Guideline Recommendations  
Commonly used for:

- UTI
- Purulent Skin and soft-tissue infections

Excellent for *S. aureus*, including MRSA



# Tetracycline Antibiotic

## Doxycycline

Dosing: Twice a day

Toxicity: Teeth staining in children (rare) May be teratogenic (rare)

C. Diff risk: Low

Guideline Recommendations


First line for:

- Ehrlichiosis and Lyme
- Chlamydia

Commonly used for:

- CAP
- Acute bacterial sinusitis
- Syphilis
- Skin and soft-tissue infections

Gram negative coverage is questionable



# Fluoroquinolones

## Advantages

Excellent oral bioavailability and good half-life

Favorable dosing schedules:

- Ciprofloxacin twice daily

- Levofloxacin daily

Adverse effects uncommon

Good distribution, great for urine

Oral option for pseudomonas coverage

## Disadvantages

Rapid development of resistance

- Typically via target mutation

- S. aureus* can develop resistance on therapy → AVOID

High risk for *C. difficile*

Toxicity is rare but can be severe:

- QT prolongation

- Aortic aneurysm or dissection

- Tendinopathy, tendon rupture

- Neurologic adverse effects – seizures, hallucinations, delirium, peripheral neuropathy

# Fluoroquinolone Antibiotic

## Ciprofloxacin

Dosing: Twice a day

Toxicity: Several

C. Diff risk: HIGH

### Guideline Recommendations

#### First line

- Only if allergy or need ORAL *pseudomonas* coverage

#### Commonly used for:

- UTI, especially pyelonephritis
- Intra-abdominal infections
- Wounds with *Pseudomonas* risk

Of note: Increasing resistance developing



# Fluoroquinolone Antibiotic

## Levofloxacin

Dosing: Once a day  
Toxicity: Several  
C. Diff risk: HIGH

Guideline Recommendations  
First line

- Only if allergy or need ORAL *pseudomonas* coverage




Commonly used for:

- CAP
- Acute bacterial sinusitis (beta-lactam based therapy preferred)

Slightly less gram negative coverage than ciprofloxacin, better gram positive



# Principles of Antibiotic Selection



# From Pathogens to Prescriptions:

## Foundations of Antimicrobial Therapy

Thank you

Question: [Emily.perry@ndsu.edu](mailto:Emily.perry@ndsu.edu)

# Resources:

- CDC Guideline for Isolation Precautions:  
<https://www.cdc.gov/infection-control/media/pdfs/Guideline-Isolation-H.pdf>
- Reportable disease:  
<https://www.hhs.nd.gov/sites/www/files/documents/DOH%20Legacy/Reportable%20Conditions%20-%20Dec%202023.pdf>